Core Viewpoint - The article emphasizes the importance of HPV vaccination and regular cervical cancer screening for women, debunking common misconceptions about the vaccine's effectiveness and necessity. Group 1: HPV Vaccination Progress - Various regions in China have initiated HPV vaccination projects, with the vaccine included in the national immunization program starting in 2025, providing free vaccinations for girls aged 13 [1]. - As of February 2026, provinces have begun vaccine procurement and are rolling out free vaccination services, with HPV vaccines available at regular vaccination sites [1]. Group 2: Misconceptions about HPV Vaccination - The claim that "getting the HPV vaccine after marriage is useless" is incorrect; the vaccine can still provide protection against uninfected HPV types even if a woman has been previously infected [2]. - The notion that "vaccination eliminates the need for cervical cancer screening" is also false; both vaccination and regular screening are essential for effective cervical cancer prevention [2]. - Women aged 35 to 64 are encouraged to undergo regular cervical cancer screenings, as the vaccine does not cover all HPV types and cannot clear existing infections [2].

Group 1 - The HPV vaccine will be included in the national immunization program starting from November 10, 2025, providing free vaccination for eligible girls aged 13 years and above born after November 10, 2011 [1][3] - Cervical cancer is one of the most common malignant tumors in the female reproductive system, and timely vaccination can significantly reduce the risk of developing cervical cancer [3] - The target population for the HPV vaccination under the national immunization program is girls aged 13 years, as vaccination before the onset of sexual activity maximizes the protective effect against HPV infection [3] Group 2 - The bivalent HPV vaccine is chosen for the program because approximately 70% of cervical cancer cases in China are associated with high-risk HPV types 16 and 18 [3] - Girls aged 9-14 are recommended to receive two doses of the bivalent HPV vaccine, which is considered the most cost-effective option for preventing infections from these two types [3] - If a girl has already received one dose of a self-paid HPV vaccine, she can still receive the free vaccine for the second dose, provided she has not completed the two doses [4][5] Group 3 - The HPV vaccine provides long-term protection, and there is currently no need for booster shots [6] - During the vaccination period, it is advised to avoid known allergens and consult healthcare providers if experiencing significant discomfort during menstruation [6] - It is recommended to wait at least two weeks between receiving the HPV vaccine and other vaccines, such as COVID-19 or influenza vaccines [6] Group 4 - Currently, there are three types of HPV vaccines available in China: bivalent, quadrivalent, and nonavalent; however, it is not recommended to receive other HPV vaccines after completing the free bivalent vaccine series due to a lack of research data [7] - Before vaccination, individuals must confirm their eligibility, including age and health status, and bring necessary documents such as a vaccination certificate and valid identification [8] - It is suggested to make appointments online to reduce waiting times and to check local vaccination clinic locations through relevant apps or programs [8]

Core Viewpoint - The incidence of cervical cancer in China is rising and becoming more prevalent among younger women, posing a significant threat to their health. Vaccination against HPV is highlighted as an effective preventive measure against high-risk HPV infections and cervical cancer [1]. Group 1: HPV Vaccination Initiative - The National Health Commission, in collaboration with the National Administration of Traditional Chinese Medicine and the National Center for Disease Control and Prevention, announced a continuation of public health service projects in 2026, including free HPV vaccinations for girls aged 13 [1]. - Research indicates that girls aged 9-14 who receive the HPV vaccine have antibody levels more than twice that of those aged 15 and older, with protection lasting over 10 years [3]. - The HPV vaccine included in the national immunization program is a bivalent vaccine requiring two doses spaced six months apart, which can effectively prevent over 70% of cervical cancer cases [3].

Core Viewpoint - Nepal's Ministry of Health and Population is launching a nationwide HPV vaccination campaign from February 8 to 27 to prevent cervical cancer among schoolgirls and out-of-school girls aged 10 to 14 [1] Group 1: Vaccination Campaign Details - The vaccination campaign targets all sixth-grade schoolgirls, 10-year-old out-of-school girls, and girls in grades seven to ten who missed vaccination last year, as well as out-of-school girls aged 11 to 14 [1] - Vaccination points will be set up at schools, nearby locations, or designated healthcare facilities, with arrangements varying by region [1] Group 2: Public Health Initiative - The Ministry of Health urges parents, guardians, and relevant parties to ensure eligible girls receive the vaccine during this period to collectively reduce the risk of cervical cancer [1]

Core Viewpoint - The province has successfully exceeded its goal of vaccinating 100,000 eligible girls with the HPV vaccine, aiming to prevent cervical cancer and promote public health [1][2]. Group 1: Project Implementation - The provincial government established a collaborative mechanism involving multiple departments to ensure the effective implementation of the HPV vaccination project [3]. - A temporary management method for vaccination subsidy funds was introduced to standardize the subsidy process and ensure proper fund allocation [3]. - After the first dose was administered, the government organized data verification to ensure compliance with the vaccination plan and maintain accurate records [3]. Group 2: Public Awareness and Education - A comprehensive promotional network was created to address parents' and girls' concerns about the HPV vaccine, utilizing both online and offline channels [4]. - The government produced educational materials and engaged experts to disseminate knowledge about cervical cancer prevention and the importance of vaccination [4]. - Local governments leveraged various media platforms to raise awareness about the HPV vaccine and its benefits, ensuring that the community is well-informed [4]. Group 3: Service Optimization - Vaccination sites were organized efficiently, with healthcare professionals ensuring safety protocols were followed during the vaccination process [5][6]. - The health department provided educational resources to enhance understanding of the vaccination process and offered extended service hours for convenience [6]. - Regular monitoring and coordination were conducted to address challenges in vaccine distribution and ensure the smooth execution of the vaccination program [6].

Core Viewpoint - Gansu Province has become the first in Northwest China to include HPV vaccination for eligible girls in its provincial public welfare initiatives, aiming to provide vaccination services to 100,000 girls by the end of 2025, reflecting a strong commitment to women's and children's health [1][11]. Group 1: Implementation Strategy - A three-tiered working system has been established, involving provincial coordination, departmental collaboration, and local implementation, with clear policies and funding support to ensure effective project execution [2][4]. - Specific implementation plans and subsidy management guidelines have been developed, detailing the vaccination process, target demographics, and departmental responsibilities [2]. Group 2: Public Awareness and Engagement - A multi-faceted promotional strategy has been created to address common concerns about vaccine safety and necessity, utilizing both online and offline channels to enhance public awareness and acceptance [5][7]. - Innovative outreach efforts have been made, including personalized communication strategies for families and targeted campaigns in areas with high numbers of left-behind children [7][9]. Group 3: Service Quality and Safety - The vaccination process has been optimized to ensure safety and efficiency, with comprehensive data collection and dynamic information management to track eligible girls [8][11]. - A focus on human-centered service has been implemented, providing various support services at vaccination sites and flexible scheduling options to accommodate different needs [9][11]. - Rigorous quality control measures have been established, including extensive training for vaccination personnel and strict adherence to safety protocols, resulting in zero major adverse reactions reported so far [11]. Group 4: Future Directions - Gansu Province plans to further enhance its women's and children's health service system by integrating various health initiatives, aiming to improve overall health outcomes for women and children in the region [11].

Core Viewpoint - Zhejiang Province is implementing HPV vaccination initiatives to enhance public health and prevent related diseases, particularly cervical cancer, by providing subsidized access to the HPV vaccine for eligible populations [1][2]. Group 1: HPV Vaccination Initiatives - The HPV vaccination program in Zhejiang will offer subsidized access to the imported nine-valent HPV vaccine for females aged 9-26 and 35-45, as well as males aged 16-26, with the last dose being free of charge [1]. - The vaccination initiative has received positive social feedback, leading to an extension of the vaccination period to accommodate demand, with the first dose deadline set for September 30, 2026, in most cities [2]. - The program aims to provide protection for women beyond the national immunization age and includes male vaccination, thereby broadening the health care support system [2]. Group 2: HPV Infection and Prevention - HPV is a common infection with over 200 types, with high-risk types being responsible for approximately 98% of cervical cancer cases in Chinese women [3][4]. - The incidence of cervical cancer in China is rising, with nearly 150,000 new cases and 60,000 deaths reported in 2022, highlighting the importance of preventive measures such as vaccination [3]. - The World Health Organization recommends that girls aged 9-14, who have not yet engaged in sexual activity, are the primary target group for HPV vaccination to achieve optimal protection [3]. Group 3: Gender Considerations in HPV Vaccination - HPV infection rates show a "bimodal" distribution among women, with peaks at ages 17-24 and 40-44, indicating the need for vaccination across different age groups [4]. - Men are also significantly affected by HPV, with a lifetime infection rate of approximately 90%, and the vaccination of both genders is essential to reduce overall infection rates and associated health risks [5][6]. - The collaborative vaccination strategy for both genders is expected to lower HPV infection rates and reduce healthcare costs related to screening and treatment [5]. Group 4: Public Health Strategy and Accessibility - The clinical guidelines recommend prioritizing HPV vaccination for females aged 9-26, with a focus on girls aged 9-14, while also including males and older females in the vaccination strategy [6]. - Zhejiang's multi-faceted approach to promoting HPV vaccination reflects a commitment to public health and aims to establish a herd immunity barrier by making vaccinations more accessible and affordable [6].

Core Viewpoint - Cervical cancer is a common malignant tumor in the female reproductive system, and the HPV vaccine is the most effective means of prevention [1] Group 1: HPV Vaccine Efficacy - The HPV vaccine stimulates the immune system to produce protective antibodies that can quickly eliminate the virus upon invasion [1] - Widespread vaccination can reduce the incidence of cervical cancer by over 70% [1] - The vaccine also significantly decreases the risk of diseases caused by HPV types 16 and 18 [1]

Core Viewpoint - Jiangsu Province is implementing HPV vaccination initiatives to enhance public health and prevent cervical cancer, aligning with national health strategies and local action plans [1][2]. Group 1: HPV Vaccination Initiatives - Starting in 2023, Jiangsu Province has included "free HPV vaccination for eligible girls" in its government welfare projects for three consecutive years, targeting first-year middle school girls [2]. - Various cities in Jiangsu are offering financial incentives for HPV vaccinations, significantly reducing economic burdens and increasing vaccination willingness among the population [2]. - The vaccination program has expanded to include women aged 9-26 and men aged 16-26, with specific financial incentives for receiving the imported nine-valent HPV vaccine [2][3]. Group 2: Health Statistics and Trends - HPV infection is common, with high-risk types causing approximately 98% of cervical cancer cases in Chinese women, highlighting the importance of early vaccination [4]. - The incidence of cervical cancer in China is rising, with nearly 150,000 new cases and 60,000 deaths reported in 2022, indicating a need for preventive measures [4]. - The age distribution of HPV infections shows peaks at 17-24 years and 40-44 years, emphasizing the necessity of vaccination across different age groups [5]. Group 3: Broader Health Implications - HPV is not exclusive to women; men also face significant health risks, with a lifetime infection rate of about 90%, which can lead to various cancers [5][6]. - Joint vaccination strategies for both genders can significantly reduce HPV infection rates and associated healthcare costs, facilitating the goal of cervical cancer elimination [6]. Group 4: Accessibility and Public Awareness - The vaccination program aims to create a robust immunity barrier by including diverse age groups and genders, thus promoting community health [7]. - Local vaccination policies have varying deadlines, and eligible individuals are encouraged to consult local health services to plan their vaccinations effectively [3][7].

Core Viewpoint - The first domestic nine-valent HPV vaccine was launched in Sichuan on December 18, providing an effective means to prevent cervical cancer, which is primarily caused by high-risk HPV infections [1] Group 1: Vaccine Information - HPV is the main cause of cervical cancer, with 99.7% of cases linked to persistent high-risk HPV infections [1] - The nine-valent HPV vaccine covers more high-risk virus subtypes compared to the two-valent and four-valent vaccines, offering broader protection [1] - The price of the domestic nine-valent HPV vaccine is 509 yuan per dose [1] Group 2: Target Population and Dosage - The vaccine is recommended for females aged 9 to 45 years, with a suggested dosage of 2 doses for those aged 9 to 17 and 3 doses for those aged 18 to 45 [1] - Eligible women can consult and make appointments through the "Sichuan Vaccination" WeChat official account [1] Group 3: Appointment and Administration - On the day of vaccination, individuals must bring valid identification, and minors need to be accompanied by a family member [1] - Vaccination appointment availability will gradually open across various locations in the province, and interested individuals are encouraged to stay updated [1]